ON THIS PAGE: You will find information about how many women are diagnosed with GTD each year and some general survival information. Remember, survival rates depend on several factors. To see other pages, use the menu on the side of your screen.
Overall, GTD is rare and often curable. In the United States, GTD accounts for less than 1% of all cancers that start in a woman's reproductive system, which is a grouping called gynecologic cancers. GTD occurs in about one pregnancy out of every 1,000 U.S. pregnancies. GTD are more common in other parts of the world, including Asia and Africa. Specifically, choriocarcinoma is rare, occurring in about two to seven pregnancies out of every 100,000 in the United States.
Nearly all women with a hydatidiform mole or low-risk gestational trophoblastic neoplasia (GTN) can be cured, often with fertility-sparing surgery alone. A placental site trophoblastic tumor can often be cured, particularly if it is found before it spreads outside the uterus. Even with faster-growing GTN, a cure may be possible with more intensive treatment with estimates at 80% to 90%.
Cancer survival statistics should be interpreted with caution. Estimates are based on data from thousands of women with this type of tumor in the United States, so the actual risk for a particular individual may be different. It is not possible to tell a woman how long she will live after a diagnosis of GTD. Learn more about understanding statistics.
Statistics source: American Cancer Society.
The next section in this guide is Medical Illustrations and it offers drawings of body parts often affected by this disease. Or, use the menu on the left side of your screen to choose another section to continue reading this guide.